Our mission is to develop effective, development-ready therapies for Alzheimer’s disease by addressing its biological complexity.
RenuMemo Therapeutics is a biotechnology company focused on the development of small-molecule therapeutics for Alzheimer’s disease.
Our programs are built on clearly defined chemical entities and rational combination strategies, designed to address the multifactorial nature of neurodegeneration while maintaining a strong focus on drug development feasibility.
To translate complex neurodegenerative biology into precise, development-ready small-molecule therapeutics.
RenuMemo Therapeutics focuses exclusively on the discovery and development of small-molecule therapeutics for Alzheimer’s disease.
Our programs are built around rationally designed combination strategies intended to address multiple biological drivers of neurodegeneration, while maintaining clear chemical definition and development feasibility.
Alzheimer’s disease presents a level of biological complexity that challenges traditional, single-mechanism drug development models.
We approach this complexity with a disciplined mindset—balancing scientific rigor with development focus—and prioritizing strategies that translate biological insight into viable drug assets.
Our efforts are focused on advancing RM02 as a defined, partner-ready small-molecule program, while building a disciplined pipeline grounded in human-relevant biology.
We pursue progress through focused execution and selective collaboration, prioritizing long-term scientific integrity and sustainable value creation.